Eryaspase Does Not Improve PFS or OS in Advanced Pancreatic Cancer
The median overall survival was 7.5 months in the eryaspase arm and 6.7 months in the chemotherapy-alone arm.
Pancreatic Cancer
COVID-19 Pandemic Did Not Affect Care of Pancreatic Cancer Patients
Patients with pancreatic ductal adenocarcinoma may have been spared the COVID-related delays in care seen for other cancers, according to researchers.
Sintilimab Improves Response to Chemotherapy in Advanced Pancreatic Cancer
The improvement in response did not translate to a survival benefit.
New Symptoms ID’d That May Indicate Pancreatic Cancer
Researchers identified 23 symptoms associated with pancreatic ductal adenocarcinoma.
2000 to 2018 Saw Increase in Incidence of Pancreatic Cancer
From 2000 to 2018, there were 283,817 cases of pancreatic cancer reported.
Survey Reveals ‘Striking’ Barriers to Accessing High-Priority Cancer Drugs
Respondents said some essential cancer drugs had substantial out-of-pocket costs, and some posed a high risk of catastrophic expenditure.
Eligibility Criteria for Pancreatic Cancer Trials Exclude More Black Patients Than White Patients
Standard eligibility criteria perpetuate racial disparities and are often not medically justifiable, according to researchers.
Napabucasin Provides No Added Benefit in Metastatic Pancreatic Cancer
The phase 3 CanStem111P study was terminated early due to futility.
Sex Inequalities Persist in Cancer Clinical Trials
Men nearly always outnumbered women, regardless of trial phase, cancer type, time period, or cancer incidence in the female population.
Rucaparib Maintenance Deemed Safe, Effective for Advanced Pancreatic Cancer
Rucaparib was active in patients with germline BRCA2, germline PALB2, and somatic BRCA2 variants.
- Loading...
Loading...
Next post in Pancreatic Cancer
Loading... 
Loading...